Celcuity Inc. Annual Report - How They Did This Year

I’ve put together this guide to help you understand Celcuity’s performance over the past year. Think of this as a "cheat sheet" to help you decide if this company fits your investment goals.

1. What does this company do?

Celcuity is a biotech company in the research phase. Their primary focus is bringing their drug, gedatolisib, to market.

Gedatolisib is designed to treat a specific type of breast cancer by blocking two biological pathways—PI3K and mTOR—that help cancer cells survive. By attacking both, the drug aims to prevent cancer from resisting standard treatments.

2. Financial performance

Because the company is currently focused on research and development, they have not yet generated product revenue. They reported a loss of approximately $118.5 million this year, driven largely by $98.2 million in clinical trial expenses.

• Cash Position: The company ended the year with roughly $142 million in cash.
• The Trade-off: To fund operations, the company issued 4.5 million new shares. This process, known as dilution, increases the total number of shares and reduces the ownership percentage of existing shareholders. With a monthly burn rate of $8–$10 million, the company relies on these capital raises to maintain its research activities.

3. Major wins and progress

Celcuity is currently moving through critical regulatory and clinical milestones:

• FDA Milestone: In January 2026, the FDA accepted the application for gedatolisib and granted "Priority Review." A final decision on approval is expected by July 17, 2026.
• Clinical Trials: The VIKTORIA-1 trial demonstrated positive results regarding progression-free survival. The company is currently conducting a larger study, VIKTORIA-2, with results anticipated in mid-2026.
• The Science: The company’s approach centers on the theory that attacking multiple survival pathways simultaneously makes it more difficult for cancer cells to adapt and resist treatment.

4. Future outlook: The "Gedatolisib" Bet

The company’s future is tied directly to the success of gedatolisib. If the FDA grants approval this summer, Celcuity plans to transition into a commercial-stage company, which will involve building a sales team and launching the product. If the drug is not approved, the company will face significant challenges and may need to explore alternative strategic options, such as finding a buyer.

5. Key risks

Investing in Celcuity is a high-stakes scenario. Consider these factors before making a decision:

• The "All-or-Nothing" Risk: Because the company has no other products in its pipeline, the failure of gedatolisib would leave the business with very little to fall back on.
• Regulatory Hurdles: FDA approval is never guaranteed; the agency could reject the application or require additional clinical trials if they have concerns regarding safety or efficacy.
• Third-Party Dependence: The company licenses its technology from Pfizer. This requires them to pay royalties and adhere to strict development deadlines. Failure to meet these contractual obligations could jeopardize the business.
• The Money Pit: The company must continue to raise capital to fund its operations. While current cash reserves are intended to last through the July 2026 decision, any unexpected delays will likely require further share issuance, leading to additional dilution for investors.

Bottom Line: You aren't buying a company with steady profits; you are betting on a single scientific breakthrough. July 2026 will be the defining moment for the company's future. Before investing, ask yourself if you are comfortable with the binary outcome of an FDA decision and the ongoing dilution required to keep the research moving forward.